SCHEMBL18735901

SCHEMBL18735901

CCOC(=O)C[C@H](C)CCC=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 5/20 0.38
TRPA1 O75762 1/20 0.38
ALOX15 P16050 3/20 0.36
TSHR P16473 3/20 0.36
CYP3A4 P08684 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
FAAH O00519 1/20 0.36
CHRM1 P11229 1/20 0.35
ADORA1 P30542 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NR1I2 O75469 1/20 0.34
PGR P06401 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
PTGS2 P35354 1/20 0.34
PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7753856 1.00 MGAM (0.40) MGAMGAASIMGAM2MAPT
SCHEMBL18736159 1.00 MGAM (0.40) MGAMGAASIMGAM2MAPT
SCHEMBL18735985 0.82 ALOX15 (0.56) MGAMGAASIMGAM2ALDH1A1
SCHEMBL18736150 0.82 ALOX15 (0.56) MGAMGAASIMGAM2ALDH1A1
SCHEMBL12446349 0.82 ALOX15 (0.56) MGAMGAASIMGAM2ALDH1A1
SCHEMBL10334455 0.81 TSHR (0.36) MGAMGAASIMGAM2MAPT
SCHEMBL10334453 0.81 TSHR (0.36) MGAMGAASIMGAM2MAPT
SCHEMBL5571591 0.81 MGAM (0.41) MGAMGAASIMGAM2ALDH1A1
SCHEMBL28055033 0.81 CYP1A2 (0.46) MGAMGAASIMGAM2MAPT
SCHEMBL5001444 0.80 MGAM (0.46) MGAMGAASIMGAM2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417383-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2024-12-19 US disclosed
CN-113024467-B PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof 米托布里奇公司 2024-08-06 CN disclosed
EP-3770146-B1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF ASTELLAS ENG SMALL MOLECULES US INCORPORATED (US) 2024-07-24 EP disclosed
CN-113004205-B PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof 米托布里奇公司 2024-07-02 CN disclosed
US-20230373948-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF Astellas Engineered Small Molecules US, Incorporated 2023-11-23 US disclosed
US-20230373948-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF Astellas Engineered Small Molecules US, Incorporated 2023-11-23 US disclosed
EP-3795566-B1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF MITOBRIDGE INC (US) 2023-04-19 EP disclosed
US-11578052-B2 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof MITOBRIDGE, INC. (US) 2023-02-14 US disclosed
CN-109071459-B PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof 米托布里奇公司 2022-08-16 CN disclosed
US-11358954-B2 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof MITOBRIDGE, INC. (US) 2022-06-14 US disclosed
US-10906885-B2 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof MITOBRIDGE, INC. (US) 2021-02-02 US disclosed
US-20200157074-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2020-05-21 US disclosed
WO-2017180818-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF MITOBRIDGE, INC. (US) 2017-10-19 WO disclosed
WO-2017062468-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF MITOBRIDGE, INC. (US) 2017-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157074-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF PPARG, PPARD, PPARA MGAM 3523/4885GAA 664/4885SI 4415/4885
US-20240417383-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF PPARG, PPARD, PPARA MGAM 3523/4885GAA 664/4885SI 4415/4885
US-20230373948-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF PPARG, PPARD, PPARA MGAM 3523/4885GAA 664/4885SI 4415/4885
US-10906885-B2 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof PPARG, PPARD, PPARA MGAM 3523/4885GAA 664/4885SI 4415/4885
US-11358954-B2 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof PPARG, PPARD, PPARA MGAM 3523/4885GAA 664/4885SI 4415/4885
US-11578052-B2 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof PPARG, PPARD, PPARA MGAM 3523/4885GAA 664/4885SI 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.